相关实验视频
Updated: Jul 19, 2025

04:39
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
1.7K
免疫检查点抑制剂诱导的甲状腺功能低下症预测了日本受试者的治疗反应
Yuichiro Iwamoto1, Tomohiko Kimura1, Kazunori Dan1
1Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School, Kurashiki, Japan.
Frontiers in endocrinology
|August 16, 2023
概括
免疫检查点抑制剂 (ICI) 治疗可以导致甲状腺功能障碍,这是常见的免疫相关不良事件. 这种功能障碍与接受ICI治疗的患者的生存率和缓解率的改善有关.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 免疫检查点抑制剂 (ICI) 与免疫相关的不良事件 (irAEs) 有关.
- 甲状腺功能障碍是常见的irAE,在接受ICI的患者中观察到.
- ICI诱导的甲状腺功能障碍的严重程度与治疗结果之间的关系尚不清楚.
研究的目的:
- 调查ICI诱导的甲状腺功能障碍程度与患者生存率和缓解率之间的关联.
- 评估甲状腺功能障碍作为ICI治疗患者的irAE的临床意义.
主要方法:
- 一项追溯观察性研究,涉及466名用ICI治疗的患者.
- 甲状腺功能障碍的分类为1级 (TSH < 10μIU/mL) 和2-4级 (TSH > 10μIU/mL或甲状腺素治疗).
- 分析与甲状腺功能障碍严重程度相关的生存率和缓解率 (RECIST标准).
主要成果:
- ICI诱导的甲状腺功能障碍发生在28.2%的患者中.
- 甲状腺功能障碍1级 (64.9%) 和2级-2级 (88.9%) 的患者与没有甲状腺功能障碍 (52.1%) 的患者相比,观察到显著更高的1年生存率.
- 与没有甲状腺功能障碍的患者相比,甲状腺功能障碍 2-4 级的患者的缓解率显著更高.
结论:
- ICI诱导的甲状腺功能障碍与改善的生存率和缓解率有显著的相关性.
- 对接受ICI的患者来说,定期监测甲状腺激素水平至关重要.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
4.7K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173

